 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

“We have received final approval from the USFDA for Clindamycin Phosphate Gel USP. Clindamycin is an antibiotic which works by stopping the growth of bacteria and helps to decrease the number of acne lesions,&quot; Zydus Lifesciences said in a regulatory filing at the exchanges.

Zydus Lifesciences gains on USFDA’s final approval for skin-care topical

Since the broader markets are overstretched, failing to clear the high might trigger some profit-booking. Traders should remain extremely stock-specific and follow strict stop-losses, advised experts

10 best bets for next 3-4 weeks as experts predict some correction from record highs

Considering the strong momentum, the index is likely to march towards 20,000 milestone in coming days, provided its holds 19,700-19,800 area, while the crucial support remains at 19,600-19,500 levels, experts said

Top 10 trading ideas for next 3-4 weeks as bulls charge Nifty towards 20,000 mark

Geojit is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 750 in its research report dated August 22, 2023.

Buy Zydus Lifesciences; target of Rs 750: Geojit

The company is slated to be included in the Nifty Next 50 index on September 29 of the ongoing fiscal.

Zydus Lifesciences gains on US FDA nod for anti-depressant drug

Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 650 in its research report dated August 12, 2023.

Accumulate Zydus Lifesciences; target of Rs 650: Prabhudas Lilladher

Nuvama downgrades Zydus to ‘hold’. It says Q1 results are unlikely to be repeated, as exclusivity of epilepsy drug Trokendi is declining and revenue from blood cancer drug Revlimid remains 'lumpy'

Zydus Lifesciences down, Nuvama downgrades stock despite a strong Q1

Zydus Life Consolidated June 2023 Net Sales at Rs 5,139.60 crore, up 26.2% Y-o-Y

Zydus Life Standalone June 2023 Net Sales at Rs 2,955.70 crore, up 49.21% Y-o-Y

Revenue for the quarter came in at Rs 5,139.6crore, 29.6 percent higher than Rs 3,964.3 crore in the same quarter of the previous fiscal, the company said in an exchange filing.

Zydus Lifesciences Q1 results: Net profit doubles to Rs 1,087 crore, beats estimates

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Watchers	213
52-Wk Low	354.10
52-Wk High	668.75

Market Cap	610.71B
Volume (M)	963,978.00
52-Wk High	668.75
52-Wk Low	354.10

ZYDUSLIFE.NSE Zydus Lifesciences Ltd.

About

Feed

News

Fundamentals